Bromelain (pharmacology)

Concentrate of proteolytic enzymes enriched in bromelain
Clinical data
Trade names	Nexobrid
Other names	Anacaulase-bcdb
AHFS/Drugs.com	UK Drug Information
License data	US DailyMed: Anacaulase;
Routes of; administration	Topical
ATC code	D03BA03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	~50% (bromelain)
Elimination half-life	11.7±3.5 (8.5–19.9) hrs
Identifiers
CAS Number	37189-34-7;
DrugBank	DB12249;
ChemSpider	none;
UNII	ZLM4P8929R;
KEGG	D03162;
CompTox Dashboard (EPA)	DTXSID901010881 ;
ECHA InfoCard	100.029.599

Bromelain, a concentrate of proteolytic enzymes from the pineapple plant, is used in medicine. It is approved in the European Union for the debridement (removal of eschar, that is dead and damaged tissue) of severe burn wounds under the brand name Nexobrid. It was developed by MediWound.

The medicine has been granted orphan drug status by the European Medicines Agency (EMA).

In other contexts, bromelain has been researched for possible anti-inflammatory effects in treating a range of conditions or diseases, but results of these studies are mixed and regarded as preliminary.

In December 2022, anacaulase-bcdb (Nexobrid) was approved for medical use in the United States.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.